Panelists discuss that successful adoption of artificial intelligence (AI) skin cancer detection tools requires proven effectiveness, easy integration into clinical workflows, appropriate reimbursement, and use as supportive aids that complement—not replace—clinical judgment.
Panelists discuss how visual examination remains the primary method for evaluating suspicious skin lesions in everyday practice, emphasizing clinical judgment, patient-reported changes, and the growing—but still limited—role of artificial intelligence (AI) tools, while underscoring the importance of vigilance, especially in high-risk and underserved populations with limited access to dermatology.
Panelists discuss the challenges of skin cancer evaluations, highlighting patient fears, systemic access barriers, and provider concerns about overreferral, while emphasizing the importance of clear communication, responsible resource use, and cautious adoption of emerging tools such as artificial intelligence (AI), with clinical judgment and trusted educational resources remaining central to care.
Panelists discuss the anxieties primary care providers face in skin cancer evaluation—particularly the fear of missing a malignancy—while highlighting challenges such as limited diagnostic confidence, delayed dermatology access, and disparities in underserved areas, emphasizing the need for better tools and support to empower frontline clinicians and improve early detection.
CD388, an investigational nonvaccine antiviral, demonstrated efficacy up to 76% against influenza in a cohort of more than 5000 healthy, unvaccinated adults.
Panelists discuss the vital role of primary care providers in early skin cancer detection, highlighting the need for improved diagnostic confidence, integration of artificial intelligence (AI) tools, and efficient workflows to overcome time and resource constraints, ultimately aiming to reduce delays and improve patient outcomes.
Atopic dermatitis is not just "another rash on the schedule. It could be the reason that patient doesn't leave the house," Shahriari says.
RAD 2025: Multidisciplinary collaboration at disease-specific meetings drives clinical and therapeutic progress in AD, Dr Yu told Patient Care.
Dermatologists aren't trained in mental health but once in practice they need to have a deep appreciation for the emotional impact of diseases like AD and a low bar for mental health referral.
At RAD 2025, Dr Yu shared hopes for more real-world data and targeted treatment approaches for chronic hand eczema.